Dupixent® (dupilumab) approved by FDA as the first and

 Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are...

Related Keywords

Japan , Paris , France General , France , Eva Schaefer Jansen , Corentine Driancourt , Felix Lauscher , Georged Yancopoulos , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Naimish Patel , Priya Nanduri , Regeneron Genetics Center , Drug Administration , Dupilumab Development Program , Nasdaq , European Union , European Medicines Agency , Head Of Global Development , Euronext , Priority Review , Global Development , Chief Scientific Officer , Dupixent Prurigo Nodularis , Worst Itch Numeric Rating Scale , Global Assessment , Regeneron Genetics , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,